Side Effects10 min readUpdated 2026-04-10

    Semaglutide Side Effects Week by Week: What to Expect Early On

    Learn what semaglutide side effects may look like week by week, including nausea, GI symptoms, appetite changes, and when to talk to a clinician.

    Written by Trimi Medical Team. Medically reviewed by Dr. Asad Niazi, MD, MPH. This article covers semaglutide side effects week by week including what to expect during the first weeks, after dose increases, and when to contact your clinician.

    Quick links: Semaglutide treatment, Wegovy dosing, and 3-month results.

    Week 1: Where Many Patients Feel the Change First

    The first week on semaglutide is often the clearest adjustment period. Some readers feel very little while others feel a strong shift right away.

    Nausea: the most commonly reported early side effect

    Earlier fullness at meals and reduced appetite

    Reduced appetite and less interest in snacking

    Mild stomach discomfort or bloating

    Fatigue or a general adjustment feeling

    Weeks 2 to 4: Finding Out What Is Temporary

    By weeks 2 to 4, many readers are trying to figure out whether symptoms are settling or getting in the way. This is often the stage where nausea starts to improve, appetite suppression becomes more familiar, and hydration starts to matter a lot more.

    This is also where patient behavior can make a big difference. Heavy meals, greasy foods, alcohol, and poor fluid intake often make the experience harder. Understanding the Wegovy dosing schedule helps set expectations for dose progression.

    Dose Increases Can Restart the Timeline

    Even if symptoms improved by week 4, readers may notice a partial reset after a dose increase.

    Nausea can return temporarily after each dose escalation

    GI sensitivity can increase as the body adjusts to the higher dose

    Appetite suppression can feel stronger again

    What Tends to Help

    Eat smaller meals rather than large ones

    Stay well hydrated throughout the day

    Avoid very heavy or greasy meals early in treatment

    Slow down dose progression when clinically appropriate

    When a Clinician Check-In Matters

    Common side effects still deserve boundaries. Readers should know that symptoms deserve real medical attention if they become severe, persistent, dehydrating, difficult to manage, or associated with severe abdominal pain or other concerning warning signs.

    For the complete treatment picture, see our semaglutide results after 3 months, what happens when you stop semaglutide, and semaglutide cost with insurance guides.

    Frequently Asked Questions

    When do semaglutide side effects usually start?

    Many semaglutide side effects appear early, especially in the first week. Readers may notice nausea, earlier fullness, reduced appetite, mild stomach discomfort, and fatigue or a general adjustment feeling. Some readers feel very little while others feel a strong shift right away. That variation is normal.

    What are the most common semaglutide side effects?

    Across the STEP program and prescribing information, the most common issues are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite. These are the side effects readers search about most frequently.

    Do semaglutide side effects improve over time?

    For many patients, GI side effects improve as the body adjusts within the first few weeks at each dose level. However, even if symptoms improved by week 4, readers may notice a partial reset after a dose increase with nausea returning, GI sensitivity increasing, and appetite suppression feeling stronger again.

    What happens to side effects after a semaglutide dose increase?

    The timeline often resets partially after dose escalation. Nausea can return, GI sensitivity can increase, and appetite suppression can feel stronger again. This is why the side-effect experience should not be thought of as a perfectly straight line but rather as connected to both time and dose changes.

    What can help manage semaglutide side effects?

    Readers often do better when they eat smaller meals, stay hydrated, avoid very heavy meals early in treatment, and slow down dose progression when clinically appropriate. These practical adjustments make the experience more manageable without crossing into personalized medical advice.

    When should I contact my clinician about semaglutide side effects?

    Contact your clinician if symptoms become severe, persistent, dehydrating, difficult to manage, or associated with severe abdominal pain or other concerning warning signs. Common side effects still deserve boundaries, and there is an important difference between expected adjustment and symptoms that need medical attention.

    How do semaglutide side effects compare to tirzepatide?

    Both medications share common GI side effects. The specific intensity and timeline can vary between patients. Some patients tolerate one medication better than the other. For a tirzepatide-specific timeline, see our tirzepatide side effects week by week guide.

    Sources & References

    1. Wegovy prescribing information. FDA.
    2. STEP program review. PubMed.
    3. Semaglutide obesity review. PubMed.

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, adjusting, or discontinuing any medication. Individual results vary. Semaglutide requires a prescription and should only be used under medical supervision.

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • In STEP 1, the most-reported adverse events with semaglutide 2.4 mg vs placebo were nausea (approximately 44% vs 16%), diarrhea (approximately 32% vs 11%), vomiting (approximately 25% vs 6%), and constipation (approximately 24% vs 11%). Most events were mild-to-moderate and most common during dose escalation. (Source: STEP 1, NEJM 2021)
    • In SURMOUNT-1, gastrointestinal adverse events occurred in approximately 81% of tirzepatide 15 mg participants vs 53% of placebo participants over 72 weeks; most resolved with continued therapy and dose adjustment. (Source: SURMOUNT-1, NEJM 2022)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 10, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Detailed hour-by-hour and day-by-day timeline of what to expect during your first week on semaglutide, tirzepatide, or other GLP-1 medications.

    Navigate GLP-1 dose titration with confidence. Week-by-week guide to managing side effects at each dose level for semaglutide and tirzepatide.

    Understand why semaglutide causes fatigue after injection, how long it lasts, and proven strategies to maintain energy levels during GLP-1 treatment.

    Clinician-reviewed Trimi guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares to brand alternatives.

    Start your GLP-1 journey — from $99/mo

    Get Started